Transdermal buprenorphine for acute postoperative pain: a systematic review
Uso da buprenorfina transdérmica na dor aguda pós-operatória: revisão sistemática
Felipe Chiodini Machado, Gilson Carone Neto, Luisa Oliveira de Paiva, Tamiris Cristina Soares, Ricardo Kenithi Nakamura, Leonardo de Freitas Nascimento, Camila Sato Campana, Lia Alves Martins Mota Lustosa, Rachel Andrade Cortez, Hazem Adel Ashmawi
Abstract
Background and objectives
Postoperative pain is still a major concern in several surgical procedures. Multimodal analgesia is best for postoperative pain management; however opioid therapy is still the main treatment for pain after surgical procedures. Transdermal buprenorphine is a partial μ agonist opioid widely used for chronic pain syndromes, with limited evidence for acute postoperative pain. A systematic review of studies examining transdermal buprenorphine for acute pain management after surgery was conducted.
Contents
Data from PubMed, Embase, The Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL via EBSCOhost, and LILACS were reviewed, including randomized clinical trials that evaluated total postoperative pain, postoperative analgesic consumption, drug-related side effects and patient satisfaction with analgesia regimen. Data from nine studies (615 patients) were included in this review. Most studies initiated transdermal buprenorphine use 6 to 48 hours before surgery, maintaining use from 1 to 28 days after the procedure. Most studies showed lower or similar postoperative pain scores, postoperative analgesic consumption and patient satisfaction comparing buprenorphine to placebo, tramadol, celecoxib, flurbiprofen and parecoxib. The incidence of side effects varied between studies, with most showing no increase in drug-related side effects with buprenorphine use, except one study, which compared buprenorphine to oral tramadol, and one to transdermal fentanyl. However, most results were derived from evidence with an overall high or unclear risk of bias.
Conclusions
Although more studies are necessary, initial results show that transdermal buprenorphine seems to be an effective and safe opioid choice for management of acute postoperative pain.
Keywords
Resumo
Justificativa e objetivos
A dor pós-operatória ainda é uma queixa importante em vários procedimentos cirúrgicos. A analgesia multimodal é a melhor conduta para a dor pós-operatória, embora a terapia com opioides ainda seja o principal tratamento para a dor após procedimentos cirúrgicos. A buprenorfina transdérmica é um opioide agonista μ amplamente prescrito nas síndromes de dor crônica, mas com limitada evidência do seu uso para dor aguda no pós-operatório. Realizamos revisão sistemática de estudos que examinaram o papel da buprenorfina transdérmica no tratamento da dor aguda pós-operatória.
Conteúdo
Revisamos os dados de PubMed, Embase, Registro Central de Ensaios Controlados Cochrane (CENTRAL), CINAHL via EBSCOhost e LILACS, incluindo estudos clínicos randomizados que avaliaram a dor pós-operatória total, consumo de analgésicos pós-operatórios, efeitos colaterais relacionados a medicamentos e satisfação do paciente com esquema de analgesia. Dados de nove estudos (615 pacientes) foram incluídos nesta revisão. A maioria dos estudos iniciou o uso transdérmico de buprenorfina 6 a 48 horas antes da cirurgia, mantendo o uso de 1 a 28 dias após o procedimento. A maioria dos estudos encontrou valores semelhantes ou menores para o escore de dor pós-operatória, consumo pós-operatório de analgésicos e satisfação do paciente quando a buprenorfina foi comparada ao placebo, tramadol, celecoxibe, flurbiprofeno e parecoxibe. A incidência de efeitos colaterais oscilou nos estudos, e a maioria não mostrou aumento de efeito colateral relacionado ao uso de buprenorfina, exceto em dois estudos, um que comparou buprenorfina ao tramadol oral e outro ao fentanil transdérmico. No entanto, a maioria dos resultados foi obtida a partir de evidências com um risco geral alto ou risco de viés impreciso.
Conclusões
Embora sejam necessários mais estudos, os resultados iniciais mostram que a buprenorfina transdérmica parece ser uma forma de administração segura e efetiva de opioide no tratamento da dor aguda pós-operatória.
Palavras-chave
References
1. Gerbershagen HJ, Aduckathil S, Van Wijck AJM, et al. Pain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical procedures. Anesthesiology. 2013;118:934-44.
2. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006;367:1618-25.
3. Chou R, Gordon DB, De Leon-Casasola OA, et al. Management of postoperative pain: A clinical practice guideline from the American pain society, the American society of regional anesthesia and pain medicine, and the American society of anesthesiologists’ committee on regional anesthesia, executive commi. J Pain. 2016;17:131-57.
4. Brennan TJ. Pathophysiology of postoperative pain. Pain. 2011;152:S33-40.
5. Vadivelu N, Anwar M. Buprenorphine in postoperative pain management. Anesthesiol Clin. 2010;28:601-9.
6. Macintyre PE, Huxtable CA. Buprenorphine for the management of acute pain. Anaesth Intensive Care. 2017;45:143-6.
7. Khannaish K, Pillarisetti S. Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res. 2015;8:859-70.
8. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96:627-32.
9. Davis MP, Pasternak G, Behm B. Treating chronic pain: an overview of clinical studies centered on the buprenorphine option. Drugs. 2018;78:1211-28.
10. Ahn JS, Lin J, Ogawa S, et al. Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review. J Pain Res. 2017;10:1963-72.
11. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain : results of a phase iii, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2004;26:1808-20.
12. Kitzmiller JP, Barnett CJ, Steiner NS, et al. Buprenorphine: revisiting the efficacy of transdermal delivery system. Ther Deliv. 2015;6:419-22.
13. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009;13:219-30.
14. Sastre JA, Varela G, Lopez M, et al. Influence of uridine diphosphate- glucuronyltransferase 2B7 (UGT2B7) variants on postoperative buprenorphine analgesia. Pain Pract. 2013;15:22-30.
15. Arshad Z, Prakash R, Gautam S, et al. Comparison between transdermal buprenorphine and transdermal fentanyl for postoperative pain relief after major abdominal surgeries. J Clin Diagn Res. 2015;9:UC01-4.
16. Desai SN, Badiger S V, Tokur SB, et al. Safety and efficacy of transdermal buprenorphine versus oral tramadol for the treatment of post-operative pain following surgery for fracture neck of femur: a prospective, randomised clinical study. Indian J Anaesth. 2017;61:225-9.
17. Kim H-J, Ahn HS, Nam Y, et al. Comparative study of the efficacy of transdermal buprenorphine patches and prolonged-release tramadol tablets for postoperative pain control after spinal fusion surgery: a prospective, randomized controlled non-inferiority trial. Eur Spine J. 2017;26:2961-8.
18. Kumar S, Chaudhary AK, Singh PK, et al. Transdermal buprenorphine patches for postoperative pain control in abdominal surgery. J Clin Diagn Res. 2016;10:UC05-8.
19. Niyogi S, Bhunia P, Nayak J, et al. Efficacy of transdermal buprenorphine patch on postoperative pain relief after elective spinal instrumentation surgery. Indian J Anaesth. 2017;61:923- 9.
20. Rivera-ruiz AP, Villegas-gómez RM, Mejía-terrazas GE. Buprenorfina transdérmica en dolor postoperatorio. Ensayo clínico controlado. Rev Mex Anestesiol. 2018;41:83-7.
21. Setti T, Sanfilippo F, Leykin Y. Transdermal buprenorphine for postoperative pain control in gynecological surgery: a prospective randomized study. Curr Med Res Opin. 2012;28:1597-608.
22. Tang J, Fan J, Yao Y, et al. Application of a buprenorphine transdermal patch for the perioperative analgesia in patients who underwent simple lumbar discectomy. Medicine (Baltimore). 2017;96:e6844.
23. Xu C, Li M, Wang C, et al. Perioperative analgesia with a buprenorphine transdermal patch for hallux valgus surgery: a prospective, randomized, controlled study. J Pain Res. 2018;11:867-73.
24. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1-10.
25. Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928–d5928.
26. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77:371-83.
27. Ferreira CA, Loureiro CAS, Saconato H, et al. Validity of Qualis database as a predictor of evidence hierarchy and risk of bias in randomized controlled trials: a case study in dentistry. Clinics (Sao Paulo). 2011;66:337-42.
28. Peelen LM, Ph D, Kalkman CJ, et al. Pain intensity on the first day after surgery. Anesthesiology. 2013118:934-44.
29. Vetter TR, Kain ZN. Role of the perioperative surgical home in optimizing the perioperative use of opioids. Anesth Analg. 2017;125:1653-7.
30. Mc Pherson M. Demystifying opioid conversion calculations: a guide for effective dosing. Pharm AS of H-S, editor. Bethesda; 2010.
31. Nelson L, Schwaner R. Transdermal fentanyl: pharmacology and toxicology. J Med Toxicol. 2008;5:230-41.
32. Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10:209-19.
Submitted date:
01/21/2020
Accepted date:
04/04/2020
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email